The DEN and CCl -Induced Mouse Model of Fibrosis and Inflammation-Associated Hepatocellular Carcinoma

Overview

Journal Curr Protoc

Specialties Biology
Science

Date 2021 Aug 9

PMID 34370903

Citations 8

Authors

Takeki Uehara

Igor P Pogribny

Ivan Rusyn

Affiliations

Soon will be listed here.

Abstract

Human hepatocellular carcinoma (HCC) develops most often as a complication of fibrosis or cirrhosis. Although most human studies of HCC provide crucial insights into the molecular signatures of HCC, they seldom address its etiology. Mouse models provide essential tools for investigating the pathogenesis of HCC, but the majority of rodent cancer models do not feature liver fibrosis. Detailed here is a protocol for an experimental mouse model of HCC that arises in association with advanced liver fibrosis. The disease model is induced by a single injection of N-nitrosodiethylamine (DEN) at 2 weeks of age followed by repeated administration of carbon tetrachloride (CCl ) from 8 weeks of age for up to 14 consecutive weeks. A dramatic potentiation of liver tumor incidence is observed following administration of DEN and CCl , with 100% of mice developing liver tumors at 5 months of age. This model has been employed for studying the molecular mechanisms of fibrogenesis and HCC development, as well as for cancer hazard/chemotherapy testing of drug candidates. © 2021 Wiley Periodicals LLC. Basic Protocol: The DEN and CCl -induced mouse model of fibrosis and inflammation-associated hepatocellular carcinoma.

Citing Articles

Liver sinusoidal endothelial cells regulate the balance between hepatic immunosuppression and immunosurveillance.

Kremer K, Khammash H, Miranda A, Rutt L, Twardy S, Anton P Front Immunol. 2025; 15:1497788.

PMID: 39896805 PMC: 11782242. DOI: 10.3389/fimmu.2024.1497788.

Light-activatable minimally invasive ethyl cellulose ethanol ablation: Biodistribution and potential applications.

Yang J, Ma C, Quinlan J, McNaughton K, Lee T, Shin P Bioeng Transl Med. 2024; 9(6):e10696.

PMID: 39545085 PMC: 11558191. DOI: 10.1002/btm2.10696.

Galectin 3-binding protein (LGALS3BP) depletion attenuates hepatic fibrosis by reducing transforming growth factor-β1 (TGF-β1) availability and inhibits hepatocarcinogenesis.

Kim D, Sung M, Park M, Sun E, Yoon S, Yoo K Cancer Commun (Lond). 2024; 44(10):1106-1129.

PMID: 39073023 PMC: 11483554. DOI: 10.1002/cac2.12600.

Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges.

Cigliano A, Liao W, Deiana G, Rizzo D, Chen X, Calvisi D Biomedicines. 2024; 12(7).

PMID: 39062197 PMC: 11274649. DOI: 10.3390/biomedicines12071624.

Extract Alleviates Acute Liver Injury by Antagonizing Inflammasome-Mediated Pyroptosis.

Kim J, Cho S, Kang S, Moon C, Yang J, Ki S Int J Mol Sci. 2023; 24(15).

PMID: 37569359 PMC: 10419291. DOI: 10.3390/ijms241511982.

References

Aravalli R, Cressman E, Steer C . Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol. 2012; 87(2):227-47. DOI: 10.1007/s00204-012-0931-2. View

Wells M, Williams E . The transgenic mouse assay as an alternative test method for regulatory carcinogenicity studies--implications for REACH. Regul Toxicol Pharmacol. 2009; 53(2):150-5. DOI: 10.1016/j.yrtph.2008.12.006. View

Luedde T, Schwabe R . NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2011; 8(2):108-18. PMC: 3295539. DOI: 10.1038/nrgastro.2010.213. View

Shiels M, OBrien T . Recent Decline in Hepatocellular Carcinoma Rates in the United States. Gastroenterology. 2020; 158(5):1503-1505.e2. PMC: 7146982. DOI: 10.1053/j.gastro.2019.12.030. View

Vucur M, Roderburg C, Bettermann K, Tacke F, Heikenwalder M, Trautwein C . Mouse models of hepatocarcinogenesis: what can we learn for the prevention of human hepatocellular carcinoma?. Oncotarget. 2011; 1(5):373-378. PMC: 3157729. DOI: 10.18632/oncotarget.170. View

El-Serag H, Rudolph K . Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132(7):2557-76. DOI: 10.1053/j.gastro.2007.04.061. View

Druckrey H, STEINHOFF D, PREUSSMANN R, Ivankovic S . [INDUCTION OF CANCER BY A SINGLE DOSE OF METHYLNITROSO-UREA AND VARIOUS DIALKYLNITROSAMINES IN RATS]. Z Krebsforsch. 1964; 66:1-10. View

Alkofer B, Lepennec V, Chiche L . Hepatocellular cancer in the non-cirrhotic liver. J Visc Surg. 2011; 148(1):3-11. DOI: 10.1016/j.jviscsurg.2010.12.012. View

Bannasch P . Strain and species differences in susceptibility to liver tumour induction. IARC Sci Publ. 1983; (51):9-38. View

10.

Heindryckx F, Colle I, Van Vlierberghe H . Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol. 2009; 90(4):367-86. PMC: 2741148. DOI: 10.1111/j.1365-2613.2009.00656.x. View

11.

Jacobson-Kram D . Cancer risk assessment approaches at the FDA/CDER: Is the era of the 2-year bioassay drawing to a close?. Toxicol Pathol. 2009; 38(1):169-70. DOI: 10.1177/0192623309351892. View

12.

Rebouissou S, Nault J . Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol. 2020; 72(2):215-229. DOI: 10.1016/j.jhep.2019.08.017. View

13.

Fausto N, Campbell J . Mouse models of hepatocellular carcinoma. Semin Liver Dis. 2010; 30(1):87-98. DOI: 10.1055/s-0030-1247135. View

14.

Chappell G, Kutanzi K, Uehara T, Tryndyak V, Hong H, Hoenerhoff M . Genetic and epigenetic changes in fibrosis-associated hepatocarcinogenesis in mice. Int J Cancer. 2013; 134(12):2778-88. PMC: 4209252. DOI: 10.1002/ijc.28610. View

15.

Farazi P, DePinho R . Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006; 6(9):674-87. DOI: 10.1038/nrc1934. View

16.

Uehara T, Ainslie G, Kutanzi K, Pogribny I, Muskhelishvili L, Izawa T . Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis. Toxicol Sci. 2013; 132(1):53-63. PMC: 3576012. DOI: 10.1093/toxsci/kfs342. View

17.

Fattovich G, Stroffolini T, Zagni I, Donato F . Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004; 127(5 Suppl 1):S35-50. DOI: 10.1053/j.gastro.2004.09.014. View

18.

Preziosi M, Poddar M, Singh S, Monga S . Hepatocyte Wnts Are Dispensable During Diethylnitrosamine and Carbon Tetrachloride-Induced Injury and Hepatocellular Cancer. Gene Expr. 2018; 18(3):209-219. PMC: 6190118. DOI: 10.3727/105221618X15205148413587. View

19.

Taha H, Elfar N, Haffez H, Hassan Z . Raptinal silver nanoparticles: new therapeutic advances in hepatocellular carcinoma mouse model. Naunyn Schmiedebergs Arch Pharmacol. 2020; 394(2):279-289. DOI: 10.1007/s00210-020-01973-4. View

20.

Sawyers C, Abate-Shen C, Anderson K, Barker A, Baselga J, Berger N . AACR Cancer Progress Report 2013. Clin Cancer Res. 2013; 19(20 Suppl):S4-98. DOI: 10.1158/1078-0432.CCR-13-2107. View